A Study to Investigate Safety and Effectiveness of BGB-16673 in Combination With Other Agents in Participants With Relapsed or Refractory B-Cell Malignancies
A Phase 1b/2, Open-Label, Master Protocol Study of BTK-Degrader BGB-16673 in Combination With Other Agents in Patients With Relapsed or Refractory B-Cell Malignancies
Sponsor: BeOne Medicines
Listed as NCT06634589, this observational or N/A phase trial focuses on B-cell Lymphoma and B-cell Malignancy and remains actively recruiting participants. Sponsored by BeOne Medicines, it has been updated 16 times since 2024, reflecting substantial change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Study Description(click to expand)This new study will check how safe and helpful a potential anticancer drug called BGB-16673 is in participants with R/R B-cell malignancies when it is given in combination with other medicines - sonrotoclax in substudy 1, zanubrutinib in substudy 2, mosunetuzumab in substudy 3, and glofitamab in substudy 4.
Our company, previously known as BeiGene, is now officially BeOne Medicines. Because some of our older studies were sponsored under the name BeiGene, you may see both names used for this study on this website.
This new study will check how safe and helpful a potential anticancer drug called BGB-16673 is in participants with R/R B-cell malignancies when it is given in combination with other medicines - sonrotoclax in substudy 1, zanubrutinib in substudy 2, mosunetuzumab in substudy 3, and glofitamab in substudy 4.
Our company, previously known as BeiGene, is now officially BeOne Medicines. Because some of our older studies were sponsored under the name BeiGene, you may see both names used for this study on this website.
Status Flow
Change History
16 versions recorded-
Apr 16, 2026 — Present [daily]
Recruiting
Phase: PHASE1/PHASE2 → None
-
Mar 2026 — Apr 2026 [monthly]
Recruiting PHASE1/PHASE2
-
Feb 2026 — Mar 2026 [monthly]
Recruiting PHASE1/PHASE2
-
Jan 2026 — Feb 2026 [monthly]
Recruiting PHASE1/PHASE2
-
Dec 2025 — Jan 2026 [monthly]
Recruiting PHASE1/PHASE2
▶ Show 11 earlier versions
-
Nov 2025 — Dec 2025 [monthly]
Recruiting PHASE1/PHASE2
-
Oct 2025 — Nov 2025 [monthly]
Recruiting PHASE1/PHASE2
-
Sep 2025 — Oct 2025 [monthly]
Recruiting PHASE1/PHASE2
-
Aug 2025 — Sep 2025 [monthly]
Recruiting PHASE1/PHASE2
-
Jul 2025 — Aug 2025 [monthly]
Recruiting PHASE1/PHASE2
-
Jun 2025 — Jul 2025 [monthly]
Recruiting PHASE1/PHASE2
-
May 2025 — Jun 2025 [monthly]
Recruiting PHASE1/PHASE2
-
Apr 2025 — May 2025 [monthly]
Recruiting PHASE1/PHASE2
-
Feb 2025 — Apr 2025 [monthly]
Recruiting PHASE1/PHASE2
-
Jan 2025 — Feb 2025 [monthly]
Recruiting PHASE1/PHASE2
Status: Not Yet Recruiting → Recruiting
-
Nov 2024 — Jan 2025 [monthly]
Not Yet Recruiting PHASE1/PHASE2
First recorded
Eligibility Summary
The purpose of this study is to measure the safety, preliminary antitumor activity, pharmacokinetics, and pharmacodynamics with BGB-16673 in combination with other agents in participants with relapsed or refractory (R/R) B-cell malignancies. This study is structured as a master protocol with separate substudies. This study currently includes four substudies, and more substudies may be added as other combination agents are identified.
Contact Information
- BeOne Medicines
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Auckland, New Zealand , Auckland, New Zealand , Bologna, Italy , Brasília, Brazil , Clayton, Australia , Dresden, Germany , Florham Park, United States , Fuzhou, China , Gdansk, Poland , Guangzhou, China and 40 more locations